| Nano-to-Submicron Hydroxyapatite Coatings for Magnesium-based Bioresorbable Implants – Deposition, Characterization, Degradation, Mechanical Properties, and Cytocompatibility Q Tian, J Lin, Rivera-Castaneda L., A Tsanhani, ZS Dunn, A Rodriguez, ... Scientific Reports 9 (810), 2019 | 49 | 2019 |
| T Cell Immunotherapy Enhanced by Designer Biomaterials ZS Dunn, J Mac, P Wang Biomaterials 217, 2019 | 40 | 2019 |
| Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy X Chen, S Yang, S Li, Y Qu, HY Wang, J Liu, ZS Dunn, GE Cinay, ... Molecular Therapy-Oncolytics 21, 144-157, 2021 | 37 | 2021 |
| Quantitative Proteomics and Metabolomics Reveal Biomarkers of Disease as Potential Immunotherapy Targets and Indicators of Therapeutic Efficacy MA MacMullan, ZS Dunn, N Graham, L Yang, P Wang Theranostics 9 (25), 7872-7888. doi: 10.7150/thno.37373, 2019 | 35 | 2019 |
| Targeting immunosuppressive tumor-associated macrophages using innate T cells for enhanced antitumor reactivity YR Li, J Brown, Y Yu, D Lee, K Zhou, ZS Dunn, R Hon, M Wilson, ... Cancers 14 (11), 2749, 2022 | 33 | 2022 |
| Engineering induced pluripotent stem cells for cancer immunotherapy Y Zhou, M Li, K Zhou, J Brown, T Tsao, X Cen, T Husman, A Bajpai, ... Cancers 14 (9), 2266, 2022 | 24 | 2022 |
| Adenosine deaminase 1 overexpression enhances the antitumor efficacy of chimeric antigen receptor-engineered T cells Y Qu, ZS Dunn, X Chen, M MacMullan, G Cinay, H Wang, J Liu, F Hu, ... Human Gene Therapy 33 (5-6), 223-236, 2022 | 21 | 2022 |
| Human γδ T cell subsets and their clinical applications for cancer immunotherapy D Lee, CJ Rosenthal, NE Penn, ZS Dunn, Y Zhou, L Yang Cancers 14 (12), 3005, 2022 | 20 | 2022 |
| Advancing cell-based cancer immunotherapy through stem cell engineering YR Li, ZS Dunn, Y Yu, M Li, P Wang, L Yang Cell Stem Cell, 2023 | 18 | 2023 |
| Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention YR Li, ZS Dunn, G Garcia Jr, C Carmona, Y Zhou, D Lee, J Yu, J Huang, ... Stem cell research & therapy 13 (1), 112, 2022 | 17 | 2022 |
| Development of stem cell-derived immune cells for off-the-Shelf cancer immunotherapies YR Li, ZS Dunn, Y Zhou, D Lee, L Yang Cells 10 (12), 3497, 2021 | 14 | 2021 |
| Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers YR Li, S Zeng, ZS Dunn, Y Zhou, Z Li, J Yu, YC Wang, J Ku, N Cook, ... Iscience 25 (9), 2022 | 12 | 2022 |
| Reducing proteolytic liability of a MMP‐14 inhibitory antibody by site‐saturation mutagenesis KB Lee, Z Dunn, X Ge Protein Science 28 (3), 643-653, 2019 | 11 | 2019 |
| Efficient facemask decontamination via forced ozone convection J Schwan, TR Alva, G Nava, CB Rodriguez, ZS Dunn, JW Chartron, ... Scientific Reports 11 (1), 12263, 2021 | 10 | 2021 |
| Generation of highly selective monoclonal antibodies inhibiting a recalcitrant protease using decoy designs KB Lee, ZS Dunn, T Lopez, Z Mustafa, X Ge Biotechnology and bioengineering 117 (12), 3664-3676, 2020 | 6 | 2020 |
| Off-the-shelf thirdparty HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers. iScience 25, 104859 YR Li, S Zeng, ZS Dunn, Y Zhou, Z Li, J Yu, YC Wang, J Ku, N Cook, ... | 5 | 2022 |
| Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering D Lee, ZS Dunn, W Guo, CJ Rosenthal, NE Penn, Y Yu, K Zhou, Z Li, ... Nature Communications 14 (1), 6942, 2023 | 3 | 2023 |
| Bioceramics for orthopaedic device applications: hydroxyapatite Q Tian, L Rivera-Castaneda, ZS Dunn, H Liu Nanobioceramics for healthcare applications, 49-77, 2017 | 3 | 2017 |
| Minimally Invasive Preclinical Monitoring of the Peritoneal Cavity Tumor Microenvironment ZS Dunn, YR Li, Y Yu, D Lee, A Gibbons, JJ Kim, TY Zhou, M Li, ... Cancers 14 (7), 1775, 2022 | 2 | 2022 |
| Phospho-proteomic analysis of CAR-T cell signaling following activation by antigen-presenting cancer cells MA MacMullan, ZS Dunn, Y Qu, P Wang, NA Graham bioRxiv, 2022.02. 24.481820, 2022 | 1 | 2022 |
